A comprehensive review of injectable contraception with special emphasis on depot medroxyprogesterone acetate.
D001315:Australia; D001794:Blood Pressure / Q000187:drug effects; D001943:Breast Neoplasms / Q000139:chemically induced; D003276:Contraceptives, Oral / Q000008:administration & dosage* / Q000009:adverse effects; D004343:Drug Implants; D005260:Female; D005298:Fertility / Q000187:drug effects; D005333:Fetus / Q000187:drug effects; D006801:Humans; D007267:Injections; D008525:Medroxyprogesterone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017258:Medroxyprogesterone Acetate; D008599:Menstruation Disturbances / Q000139:chemically induced; D009369:Neoplasms / Q000139:chemically induced; D009640:Norethindrone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D013924:Thrombophlebitis / Q000139:chemically induced; D002583:Uterine Cervical Neoplasms / Q000139:chemically induced
D003276:Contraceptives, Oral; D004343:Drug Implants; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone; C024319:norethindrone enanthate; D009640:Norethindrone